Participated · Series A · Feb 2026

Avisi Technologies, Inc. is a clinical-stage company focused on creating novel ophthalmic solutions, most notably VisiPlate®, an investigational aqueous shunt engineered from an ultrathin, patented metamaterial designed to maintain intra-ocular pressure through multiple microchannels that resist blockage and scarring. The device targets the unmet need for long-term, low-maintenance glaucoma care and is currently being evaluated in the FDA IDE-approved SAPPHIRE pivotal trial that is enrolling patients across the United States. Avisi’s broader pipeline includes V-001, a sustained intraocular drug-delivery platform, and VisiPlate-S, a drainage device intended for use during cataract surgery. Proceeds from its latest financing will fund the SAPPHIRE trial and advance additional pipeline programs addressing the full spectrum of glaucomatous disease. The company has garnered recognition and non-dilutive support from the National Science Foundation, the Glaucoma Research Foundation, Johnson & Johnson JLABS, and other industry accelerators. Current investors include both venture funds and angel networks, underscoring diversified backing for its development roadmap. No revenue or user figures have been disclosed to date.

Participated · Series A · Apr 2024

Adaptilens is a Boston, MA-based pre-clinical biotech focused on advancing the standard of care for cataract surgery. Its core product, the Adaptilens A-IOL, is a soft, flexible, biomimetic accommodating intraocular lens that responds to the eye's natural signal to focus and aims to eliminate the need for eyeglasses or contact lenses. The company intends to use the new funding to drive development of the A-IOL through first-in-human trials. Adaptilens is led by founder and CEO Liane Clamen. The company raised $17.5M in a Series A round led by Perceptive Xontogeny Venture Funds, with participation from Pillar VC, 380 Cap, and Accanto Partners. As a pre-clinical company, its near-term milestones are clinical development steps rather than commercial deployment. Adaptilens is a Boston, MA-based company developing an accommodating intraocular lens (AdaptilensTM) that mimics the natural human lens. Led by Founder and CEO Dr. Liane Clamen, the device aims to give patients excellent near, intermediate, and distance vision without eyeglasses or contact lenses. The lens will initially be used for patients with cataracts. Adaptilens could also be used to correct a variety of refractive errors, including presbyopia. The company raised $1.6M in seed funding to support development of the accommodating intraocular lens. The round was led by Pillar VC with participation from Accanto Partners.

Participated · Seed · Sep 2013

Catalant Technologies operates an Expert Marketplace and a SaaS product that connect companies with freelance professionals as an alternative to traditional consulting firms. The company says it works with 35 percent of Fortune 1000 companies, including Pfizer and DuPont. Catalant positions freelancers as cost-effective, more agile options for strategic work in areas such as supply chain, data analytics, and project management. The company called 2020 a “watershed year” with record demand on its platform and said the pandemic accelerated an existing shift toward independent work. Catalant plans to use the new funding to scale its business and team to meet rising demand. The eight-year-old, Boston-based company has raised more than $100 million to date. Catalant Technologies offers a software and services platform for managing strategy execution, work planning, resource management, and insights and reporting. Its Resources module provides access to more than 65,000 independent experts and 1,000 consulting firms in 127 countries, supporting enterprise portfolio management and transformation workstreams. Customers include Anheuser‑Busch InBev, MassMutual, Highmark Health and Pfizer. Founded in 2013 as an online marketplace to match companies with consultants, Catalant has expanded into software for centers of excellence, organizational redesigns, post‑merger integrations, and agile transformations. The company recently raised a $35M Series E and expanded its debt facility to scale its product offering and enter new global markets, bringing total equity and debt funding to more than $100M. The financing and debt expansion are intended to scale the product and accelerate global expansion. Catalant provides a suite of software products that combine clients’ internal talent with a global network of more than 40,000 independent consultants and boutique firms to form dynamic talent pools. The platform matches companies to experts for work across research, strategy, marketing, finance, sales, operations and product initiatives. Led by co-CEOs and co-founders Rob Biederman and Patrick Petitti, Catalant serves thousands of global clients, including nearly one quarter of the Fortune 100. The company plans to use newly raised funds to further develop its software products and matching capabilities and to educate corporate decision makers on incorporating dynamic talent into strategic plans. Financially, Catalant has raised more than $73M in total financing to date and maintains a debt facility for ongoing financing needs. HourlyNerd is a Boston-based on-demand staffing platform that provides programming and other skilled staff for short-term projects without companies having to recruit or hire. The company is shifting toward enterprise customers and is updating its platform to include analytics and services to help customers manage time, work product and staffing requirements over time. At its core it matches skilled workers to project needs and is building tools to measure performance and incentivize on-demand talent. HourlyNerd currently has 65 employees and claims around 10 percent of the Fortune 500 as customers, including Pfizer and GE. The firm sees a future of more project-based skilled work and is positioning its platform as a full-service solution for large companies. Financially, it has raised a $22 million Series C and had previously raised around $12 million in total. HourlyNerd is a Boston, MA-based online talent marketplace that links elite independent freelancers and top MBA students who have worked at leading consulting firms and investment banks with businesses. Led by co-CEOs and co-founders Rob Biederman and Pat Petitti, the platform attracted over 4,500 companies using more than 10,000 consultants from around the country and the world within a few months via referrals, social network mentions and word of mouth. The company raised $7.8M in a Series B round led by Highland Capital Partners, with participation from GE Ventures, Greylock Partners, Intuit founder Scott Cook, the Kraft Group, angel investor Semil Shah, former Etsy CEO Maria Thomas, Rent the Runway Founder/CEO Jennifer Hyman and Suffolk Equity Partners. HourlyNerd said it will use the funds to continue to expand its technology platform. The Series B follows a Series A financing 11 months earlier led by Highland Capital Partners and Greylock Partners and an earlier seed round led by angel investor Mark Cuban.